Clinical Validation of NEC featured on the cover of Clinical & Experimental Allergy

Clinical validation data from our Naturalistic Exposure Chamber (NEC) was featured on the cover of this month’s issue of Clinical and Experimental Allergy (Volume 52, Issue 2, February 2022): Cat allergen exposure in a naturalistic exposure chamber: A prospective observational study in cat-allergic subjects

This prospective observational study, performed in collaboration with Regeneron Pharmaceuticals, observed the response of 30 cat-allergic asthmatics upon two cat allergen exposures in RMT’s NEC.

“This study establishes the safety and feasibility of the NEC to provoke a reproducible EAR and a highly reproducible average FEV1 in cat- allergic mild asthmatics, and demonstrates the effectiveness of aerosolizing Fel d 1 using a modified vacuum cleaner. Our study findings may inform the design of interventional clinical trials of novel cat-specific anti-allergic therapies for the prevention of allergic rhinitis and asthma in the cat-allergic population.”

This research was made possible through the efforts of our clinical team, led by Isabel Dao, our engineering team, led by Dr. Laura Haya, and the Early Clinical Development and Experimental Sciences team at Regeneron Pharmaceuticals. Congratulations to all on this important publication!

You can read the full article in Clinical & Experimental Allergy here.